


PITUITARY APOPLEXY AND COVID-19 INFECTION/VACCINATION

Aliberti L.¹, Gagliardi I.¹, Rizzo R.², Bortolotti D.², Schiuma G.², Franceschetti P.³, Zatelli MC.¹ & Ambrosio MR.¹ ¹ Department of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy; ² Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy ³Endocrine Unit, Azienda Ospedaliero-Universitaria Di Ferrara, Cona/Ferrara, Italy.

CASE REPORT

A 50-year-old man was admitted to our hospital for vomit, nausea, diplopia and headache resistant to analgesic drugs. Symptoms started the day after his third COVID-19 mRNA vaccine (Moderna) whereas SARS-CoV-2 nasal swab was negative. Pituitary MRI showed recent bleeding in macroadenoma (pituitary apoplexy). A stress dose dexamethasone was started due to the risk of adrenal insufficiency and to reduce oedema

1 st day	2 nd day	4 th day	5 th day	6 th day
SARS-CoV-	Nausea, Vomit,	Persistence	Persistence of	Persistence
2 Vaccine	Severe Headache,	of headache	headache (Pain	of headache
(Moderna)	Diplopia, Fever,	(Pain VAS	VAS 8/10) and	(Pain VAS
	Hypothension	8/10),	diplopia;	6/10)
	SARS-CoV-2 nasal	diplopia and	Increased fever	
	swab negative	fever	(38.5 °C)	



Biochemistry showed secondary hypogonadism;

lymphocyte infiltrate

BIOCHEMISTRY

inflammatory markers were elevated as well as white blood	TSH 0.41 μIU/mL (n.v. 0.25-4.5)	PRL 5.1 ng/mL (nv 5-20 ng/ml)	
cells count, fibrinogen and D-dimer; platelets were within the low normal reference range	fT4 7.1 pg/mL (n.v. 5.5-12)	VES: 19 mm (nv 0-18 mm)	
the low hormal reference range	FSH 1.9 mIU/mL (n.v. 1.2- 8.6)	CRP: 1.93 mg/dl (n.v. < 0.5)	
	LH 0.6 mIU/mL (n.v. 1.3- 8)	D-dimer: 0.59 mg/l (n.v. < 0.5)	
Pituitary tumour transsphenoidal resection was performed	Testosterone 0.29 ng/ml (n.v. 2.35-3.5)		
and pathology report was consistent with pituitary			
adenoma with focal haemorrhage and necrosis; we found			
immunohistochemical evidence for SARS-CoV-2 nearby			
pituitary vessels, in the presence of an evident			

DISCUSSION

✓ There are few reports of pituitary apoplexy after COVID-19 vaccination and infection. ✓ The cross-reaction between SARS-CoV-2 proteins and tissue antigens could lead to pituitary autoimmunity ✓ COVID-19-associated coagulopathy includes activation of the coagulation system, inhibition of fibrinolysis and release of prothrombotic mediators, causing microemboli that might lead to infarction of the pituitary adenoma

- ✓ Pituitary stimulation and cytokine storm occurring in the infectious state may lead to acute increased pituitary blood demand precipitating apoplexy
- ✓ The development of anti-PF4/heparin antibodies after vaccine administration may occur, determining complement activation and induction of both coagulopathy, thrombocytopenia and bleeding

✓ Ours is the first case of SARS-CoV-2 evidence in pituitary tissue, suggesting that, possibly, endothelial infection of pituitary vessels might be present before vaccination, supporting the hypothesis that the patient could have experienced an asymptomatic SARS-CoV-2 infection that persisted at CNS level, which could be implicated in the apoplexy onset. Our case underlines that SARS-CoV-2 can associate with apoplexy by

